Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts
JAMA
.
2018 Feb 27;319(8):776-778.
doi: 10.1001/jama.2017.21897.
Authors
Joshua D Wallach
1
,
Joseph S Ross
2
3
Affiliations
1
Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, Connecticut.
2
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
3
Associate Editor.
PMID:
29486013
DOI:
10.1001/jama.2017.21897
No abstract available
Publication types
Editorial
Comment
MeSH terms
Amines
Cyclohexanecarboxylic Acids*
Gabapentin
Humans
Off-Label Use*
Product Surveillance, Postmarketing
gamma-Aminobutyric Acid
Substances
Amines
Cyclohexanecarboxylic Acids
gamma-Aminobutyric Acid
Gabapentin